When considering a strict interpretation of the OMT criterion in the trial scenario (S12 Table in the S1 Appendix), and in both scenarios considering all patients with atrial fibrillation as ineligible (S13 Table in the S1 Appendix), eligible patients were overall younger, and had fewer comorbidities and lower NT-proBNP, as compared to eligible patients in the main analysis. This evidence concerns the gene NPPB and atrial fibrillation.